We aimed to evaluate the effectiveness and safety of bismuth-containing quadruple
therapy plus postural change after dosing for Helicobacter pylori
eradication in gastrectomized patients. We compared 76 gastric stump patients with
H. pylori infection (GS group) with 50 non-gastrectomized
H. pylori-positive patients who met the treatment indication
(controls). The GS group was divided into GS group 1 and GS group 2. All groups were
administered bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin
(1.0 g), and furazolidone (100 mg) twice daily for 14 days. GS group 1 maintained a
left lateral horizontal position for 30 min after dosing. H. pylori
was detected using rapid urease testing and histologic examination of gastric mucosa
before and 3 months after therapy. Mucosal histologic manifestations were evaluated
using visual analog scales of the updated Sydney System. GS group 1 had a higher
prevalence of eradication than the GS group 2 (intention-to-treat [ITT]: P=0.025;
per-protocol [PP]: P=0.030), and the control group had a similar prevalence. GS group
2 had a lower prevalence of eradication than controls (ITT: P=0.006; PP: P=0.626).
Scores for chronic inflammation and activity declined significantly (P<0.001) 3
months after treatment, whereas those for atrophy and intestinal metaplasia showed no
significant change. Prevalence of adverse reactions was similar among groups during
therapy (P=0.939). A bismuth-containing quadruple therapy regimen plus postural
change after dosing appears to be a relatively safe, effective, economical, and
practical method for H. pylori eradication in gastrectomized
patients.